Enrolling 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher (without diabetes), SELECT showed that semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a mean follow-up of nearly 40 months
However, in individuals with normal B12 status, additional supplementation does not enhance metabolic rate or promote fat oxidation
The product sold by clinics is a synthetic 15-amino-acid peptide manufactured by "solid-phase synthesis", administered under the skin, into the muscle or a joint, or intravenously, often at higher doses for weeks
Potential therapeutic applications of bee venom on skin disease and its mechanisms: a literature review
One sample contained none of the advertised peptide at all